Gray zone: a case report on borderline mucinous tumor
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20252506Keywords:
Borderline ovarian tumors, Fertility sparing surgery, Laparotomy, Salpingo-oopherectomyAbstract
Borderline ovarian tumors (BOTs) represent an intermediate form between benign and malignant epithelial ovarian neoplasms, with mucinous subtype accounting for a significant proportion. These tumors often present in women of reproductive age and are frequently diagnosed at an early stage. We report the case of a 25-year-old unmarried woman with regular menstrual cycles who was incidentally found to have a complex left adnexal mass during routine imaging. Clinical examination revealed a firm, midline abdominopelvic mass corresponding to 20 weeks’ uterine size. Tumor markers, including CA-125, CEA, CA 19-9, AFP, and LDH, were within normal limits. MRI pelvis revealed a 15 cm mixed solid-cystic lesion in the left adnexa. Intraoperatively, a unilateral ovarian mass with no evidence of extraovarian spread was noted. Frozen section was suggestive of a borderline mucinous tumor. The patient underwent a fertility-sparing staging laparotomy including left salpingo-oophorectomy, infracolic omentectomy, appendicectomy, pelvic lymph node dissection, and peritoneal biopsies. Final histopathology confirmed a borderline mucinous tumor, FIGO Stage IA. This case highlights the importance of thorough preoperative evaluation and intraoperative decision-making in young women with adnexal masses. Fertility-sparing surgery with complete staging offers an excellent prognosis in early-stage borderline mucinous ovarian tumors, with the added benefit of preserving reproductive potential.
Metrics
References
Nayyar N, Lakhwani P, Goel A, Pande PK, Kumar K. Management of Borderline Ovarian Tumors-Still a Gray Zone. Indian J Surg Oncol. 2017;8(4):607-14. DOI: https://doi.org/10.1007/s13193-017-0697-3
Du Bois AD, Ewald-Riegler N, Du Bois O, Harter P. Borderline tumors of the ovary-a systematic review. Geburtshilfe Frauenheilkunde. 2009;69(09):807-33. DOI: https://doi.org/10.1055/s-0029-1186007
Yokoyama Y, Moriya T, Takano T, Shoji T, Takahashi O, Nakahara K, Yamada H, et al. Clinical outcome and risk factors for recurrence in borderline ovarian tumours. Br J Cancer. 2006;94(11):1586-91. DOI: https://doi.org/10.1038/sj.bjc.6603139
Prat J. Pathology of borderline and invasive cancers. Best Pract Res Clin Obstet Gynaecol. 2017;41:15-30. DOI: https://doi.org/10.1016/j.bpobgyn.2016.08.007
Singer G, Oldt R 3rd, Cohen Y, Wang BG, Sidransky D, Kurman RJ, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst. 2003;95(6):484-6. DOI: https://doi.org/10.1093/jnci/95.6.484
Uzan C, Muller E, Kane A, Rey A, Gouy S, Bendiffallah S, et al. Prognostic factors for recurrence after conservative treatment in a series of 119 patients with stage I serous borderline tumors of the ovary. Ann Oncol. 2014;25(1):166-71. DOI: https://doi.org/10.1093/annonc/mdt430
Valentin L. Use of morphology to characterize and manage common adnexal masses. Best Pract Res Clin Obstet Gynaecol. 2004;18(1):71-89. DOI: https://doi.org/10.1016/j.bpobgyn.2003.10.002
Pai RK, Longacre TA. Appendiceal mucinous tumors and pseudomyxoma peritonei: histologic features, diagnostic problems, and proposed classification. Adv Anat Pathol. 2005;12(6):291-311. DOI: https://doi.org/10.1097/01.pap.0000194625.05137.51
Morice P, Camatte S, El Hassan J, Pautier P, Duvillard P, Castaigne D. Clinical outcomes and fertility after conservative treatment of ovarian borderline tumors. Fertil Steril. 2001;75(1):92-6. DOI: https://doi.org/10.1016/S0015-0282(00)01633-2
Downloads
Published
How to Cite
Issue
Section
